Downloads: 101

Files in This Item:
File Description SizeFormat 
cancers12040775.pdf252.23 kBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNakano, Shigeharu
dc.contributor.authorEso, Yuji
dc.contributor.authorOkada, Hirokazu
dc.contributor.authorTakai, Atsushi
dc.contributor.authorTakahashi, Ken
dc.contributor.authorSeno, Hiroshi
dc.contributor.alternative中野, 重治
dc.contributor.alternative恵荘, 裕嗣
dc.contributor.alternative髙井, 淳
dc.contributor.alternative高橋, 健
dc.contributor.alternative妹尾, 浩
dc.date.accessioned2020-04-16T01:08:59Z-
dc.date.available2020-04-16T01:08:59Z-
dc.date.issued2020-04-01
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/2433/250362-
dc.description.abstractHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death since most patients are diagnosed at advanced stage and the current systemic treatment options using molecular-targeted drugs remain unsatisfactory. However, the recent success of cancer immunotherapies has revolutionized the landscape of cancer therapy. Since HCC is characterized by metachronous multicentric occurrence, immunotherapies that induce systemic and durable responses could be an appealing treatment option. Despite the suppressive milieu of the liver and tumor immunosurveillance escape mechanisms, clinical studies of checkpoint inhibitors in patients with advanced HCC have yielded promising results. Here, we provide an update on recent advances in HCC immunotherapies. First, we describe the unique tolerogenic properties of hepatic immunity and its interaction with HCC and then review the status of already or nearly available immune checkpoint blockade-based therapies as well as other immunotherapy strategies at the preclinical or clinical trial stage.
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherMDPI AG
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.subjecthepatocellular carcinoma
dc.subjectimmunotherapy
dc.subjectimmune checkpoint inhibitor
dc.subjectPD-1
dc.subjectCTLA-4
dc.subjectcombination therapy
dc.titleRecent Advances in Immunotherapy for Hepatocellular Carcinoma
dc.type.niitypeJournal Article
dc.identifier.jtitleCancers
dc.identifier.volume12
dc.identifier.issue4
dc.relation.doi10.3390/cancers12040775
dc.textversionpublisher
dc.identifier.artnum775
dc.identifier.pmid32218257
dc.identifier.kaken17K09421
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.